Scarica l'app Stockscreener
26.19
2.96%
-0.80
Dopo l'orario di chiusura:
26.19
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Insider Monkey
Jefferies cuts Mineralys Therapeutics price target on drug concerns By Investing.com - Investing.com Australia
Jefferies cuts Mineralys Therapeutics price target on drug concerns - Investing.com
Stifel reiterates Buy rating on Mineralys stock, $52 target By Investing.com - Investing.com Nigeria
BofA raises Mineralys Therapeutics stock price target on NDA progress By Investing.com - Investing.com Nigeria
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha
Mineralys Therapeutics price target raised to $51 from $46 at BofA - TipRanks
Stifel reiterates Buy rating on Mineralys stock, $52 target - Investing.com
BofA raises Mineralys Therapeutics stock price target on NDA progress - Investing.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight - GuruFocus
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Ins - GuruFocus
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - Bitget
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c) - TipRanks
Mineralys Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast - Investing.com
Mineralys Therapeutics and Lorundrostat: Clinical Development, Competitive Landscape, and Regulatory Overview for Hypertension Therapy 2122273536 - Minichart
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Mineralys Therapeutics 10-K: $0 Revenue, $(2.29) EPS - TradingView
MINERALYS THERAPEUTICS ($MLYS) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss - marketscreener.com
David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions - Stock Titan
FDA accepts Mineralys (NASDAQ: MLYS) NDA for lorundrostat in hypertension - Stock Titan
Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026 - Stock Titan
Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings - TipRanks
Mineralys Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Mineralys earnings in focus as FDA lorundrostat decision looms By Investing.com - Investing.com South Africa
Mineralys earnings in focus as FDA lorundrostat decision looms - Investing.com
How Investors Are Reacting To Mineralys Therapeutics (MLYS) FDA Acceptance Of Lorundrostat Hypertension NDA - simplywall.st
Capital International Investors Sells 505,624 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data By Investing.com - Investing.com UK
Mineralys Shares Climb After FDA Accepts NDA for Blood Pressure Medication - Bitget
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat
Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise - Stock Titan
3 Reasons Not to Sleep on ResMed Stock - AOL.com
H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance - Investing.com UK
Mineralys blood pressure drug under FDA review (MLYS:NASDAQ) - Seeking Alpha
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap DownHere's What Happened - MarketBeat
H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance By Investing.com - Investing.com India
Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data - Investing.com
Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis
Why Mineralys Therapeutics Stock Is Sinking Today - TipRanks
Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA - TipRanks
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):